# NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS.US)

Canonical: https://gigainvestors.com/s/NAMS

Analysis as of: 2026-10-16T07:30:31.343Z. 

Listing currency: USD. Reporting currency: USD.

## Verdict

Not enough history yet

Quality tests for Buy: not passed (profit record: fail; earnings resilience is evidence only). Published buy qualification: no.

Share price: $20.62 per share; close as of 2026-10-15.

## Checklist

### understandable: na

### moat: na

### economics: na

### management: na

### accounting: na

## Holders

- [Lee Ainslie](https://gigainvestors.com/mc): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Andreas Halvorsen](https://gigainvestors.com/vg): tracked 13F investor; follow the investor page for holding quarter and amounts.

## Price story

Down 50% since Nov 2025

Story as of 2026-10-16T10:01:28.799Z; price observation 2026-10-15.

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### How it makes money

Operates in biotechnology; annual sales are USD 22.5 million.

- Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm (filed 2026-02-18); FY2025: revenue 22503000; grossProfit 22444000; margin = grossProfit / revenue.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-15); NAMS.US: NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

### Why customers stay

Margins ranged from 99.7% to 100% during 2023–25.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-18); FY2023: grossProfit / revenue = 100%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-18); FY2024: grossProfit / revenue = 100%.

- Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm (filed 2026-02-18); FY2025: grossProfit / revenue = 99.7%.

### Where the cash goes

Paid no dividends in 5 years.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-18); Dividend observations: [[2021,0],[2022,0],[2023,0],[2024,0],[2025,0]]. Zero only counted when supported by a complete cash-flow statement.

### Are managers owners

Insiders own 0.9% of the company.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-15); NAMS.US SharesStats.PercentInsiders = 0.895 percentage points; cache date 2026-10-15.

### What the price says

The price is 108.5 times annual sales; cash earnings are negative.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-18); Closing price 20.62 USD; reporting-to-trading FX 1; FY2025 annual sales per share 0.19002023327472567; price multiple 108.51475995289518. FY2025 cash earnings/share -1.721311578540037. Closing-price date 2026-10-15.

## Monthly share-price history (USD per share)

- 2021-02: $10.22 per share

- 2021-03: $9.96 per share

- 2021-04: $9.95 per share

- 2021-05: $9.70 per share

- 2021-06: $9.76 per share

- 2021-07: $9.68 per share

- 2021-08: $9.66 per share

- 2021-09: $9.82 per share

- 2021-10: $9.81 per share

- 2021-11: $9.77 per share

- 2021-12: $9.75 per share

- 2022-01: $9.80 per share

- 2022-02: $9.79 per share

- 2022-03: $9.83 per share

- 2022-04: $9.86 per share

- 2022-05: $9.86 per share

- 2022-06: $9.87 per share

- 2022-07: $9.91 per share

- 2022-08: $9.95 per share

- 2022-09: $9.97 per share

- 2022-10: $10.02 per share

- 2022-11: $8.10 per share

- 2022-12: $10.90 per share

- 2023-01: $13.38 per share

- 2023-02: $13.20 per share

- 2023-03: $13.26 per share

- 2023-04: $14.23 per share

- 2023-05: $13.86 per share

- 2023-06: $11.89 per share

- 2023-07: $11.52 per share

- 2023-08: $10.31 per share

- 2023-09: $9.25 per share

- 2023-10: $9.00 per share

- 2023-11: $9.76 per share

- 2023-12: $11.17 per share

- 2024-01: $20.47 per share

- 2024-02: $22.84 per share

- 2024-03: $23.65 per share

- 2024-04: $21.81 per share

- 2024-05: $18.75 per share

- 2024-06: $19.21 per share

- 2024-07: $17.12 per share

- 2024-08: $16.42 per share

- 2024-09: $16.60 per share

- 2024-10: $17.02 per share

- 2024-11: $19.85 per share

- 2024-12: $25.70 per share

- 2025-01: $22.29 per share

- 2025-02: $21.00 per share

- 2025-03: $20.47 per share

- 2025-04: $19.13 per share

- 2025-05: $18.11 per share

- 2025-06: $18.11 per share

- 2025-07: $21.81 per share

- 2025-08: $24.05 per share

- 2025-09: $28.44 per share

- 2025-10: $37.95 per share

- 2025-11: $41.30 per share

- 2025-12: $35.08 per share

- 2026-01: $31.12 per share

- 2026-02: $35.46 per share

- 2026-03: $32.01 per share

- 2026-04: $28.56 per share

- 2026-05: $33.68 per share

- 2026-06: $33.89 per share

- 2026-07: $27.79 per share

- 2026-08: $25.34 per share

- 2026-09: $24.32 per share

- 2026-10: $20.62 per share

## Annual estimated value (USD per share)

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

## Sources

[Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm); period 2025-12-31, filed 2026-02-18.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.

## Reported holder observations

- [Lee Ainslie](https://gigainvestors.com/mc): 3,267,802 NAMS shares; USD 110,746,000 reported position value; 1% of portfolio; add; quarter 2026 Q2.
- [Andreas Halvorsen](https://gigainvestors.com/vg): 4,203,567 NAMS shares; USD 142,459,000 reported position value; 0.41% of portfolio; hold; quarter 2026 Q2.

# NAMS — Newamsterdam Pharma Co Nv

Held by 2 investors · USD 253,205,000 total · 2026 Q2 · reported price USD 33.89 (split-adjusted).
Page: https://gigainvestors.com/s/NAMS

## Holders (2026 Q2)

| Investor | Value | % of their portfolio | This quarter |
|---|---:|---:|---|
| Andreas Halvorsen (https://gigainvestors.com/vg) | USD 142,459,000 | 0.4% | hold |
| Lee Ainslie (https://gigainvestors.com/mc) | USD 110,746,000 | 1.0% | add +49.46% |

## Total held by quarter

- 2022 Q4: USD 39,490,271 · 1 holder · USD 10.52
- 2023 Q1: USD 52,629,293 · 1 holder · USD 13.44
- 2023 Q2: USD 77,577,078 · 1 holder · USD 11.89
- 2023 Q3: USD 74,227,226 · 1 holder · USD 9.25
- 2023 Q4: USD 89,634,391 · 1 holder · USD 11.17
- 2024 Q1: USD 189,780,962 · 1 holder · USD 23.65
- 2024 Q2: USD 154,151,894 · 1 holder · USD 19.21
- 2024 Q3: USD 133,207,779 · 1 holder · USD 16.60
- 2024 Q4: USD 188,343,453 · 2 holders · USD 25.70
- 2025 Q1: USD 154,098,221 · 2 holders · USD 20.47
- 2025 Q2: USD 154,123,489 · 2 holders · USD 18.11
- 2025 Q3: USD 226,959,192 · 2 holders · USD 28.44
- 2025 Q4: USD 213,910,578 · 2 holders · USD 35.08
- 2026 Q1: USD 204,542,908 · 2 holders · USD 32.01
- 2026 Q2: USD 253,205,000 · 2 holders · USD 33.89